Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 91 Mendeley

Summary X

So far, Altmetric has seen 13 X posts from 7 X users, with an upper bound of 23,817 followers.

RT @sitcancer: #JITC Research: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with r…

07 Jul 2018

Reply Repost Favourite

RT @sitcancer: #JITC Research: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with r…

07 Jul 2018

Reply Repost Favourite

RT @sitcancer: #JITC Research: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with r…

06 Jul 2018

Reply Repost Favourite

Why post this garbage data from a drug that doesn't even hit the pathway it's supposed to... And even if it did hit ido, probably wouldn't work anyways lol $nlnk https://t.co/XqphsI1Rqw

06 Jul 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 9 additional X posts.